LONDON--(BUSINESS WIRE)--The global hedgehog pathway inhibitors market size is poised to grow by USD 241.31 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of more than 11% during the forecast period.
Read the 135-page research report with TOC on "Hedgehog pathway inhibitors market by product (BCC and AML), and geography (North America, Europe, Asia, and ROW) 2019 - 2023" at
The market is driven by the high risk factors for BCC and AML. In addition, the growth of geriatric population is expected to further boost the growth of the hedgehog pathway inhibitors market.
The high risk factors for BCC and AML is the major reason for the growth of the hedgehog pathway inhibitors market. There are many risk factors associated with the development of BCC and AML, such as exposure to UV radiation, history of skin cancer, chronic infections, skin inflammations, exposure to certain chemicals, and smoking. Such risk factors are increasing the prevalence of BCC and AML, which is expected to fuel the demand for hedgehog pathway inhibitors during the forecast period.
The incidence of hedgehog pathway-related cancer types, including AML, increases with age. Advanced age leads to an increase in frailty and comorbidities, which will have a major impact on the tolerance of AML patients to intensive treatment modalities. Moreover, physiological changes and poor tolerance to aggressive treatments with aging decreases the treatment outcomes. This increases the prevalence of AML and BCC among aged people, which will fuel the demand for hedgehog pathway inhibitors.
For More Information: Speak to an Analyst
The report includes detailed profiles of the leading companies & prominent vendors of the market:
- F. Hoffmann-La Roche Ltd.
- Inhibitor Therapeutics Inc.
- MAX BioPharma Inc.
- Mayne Pharma Group Ltd.
- PellePharm Inc
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
Market Segmentation by Product:
The hedgehog pathway inhibitors market can be broadly categorized into the following segments:
Key Regions for the Hedgehog Pathway Inhibitors Market:
Featuring a breakdown of region-wise market shares until 2019.
- North America
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Related Reports on Healthcare are:
Phosphoinositide 3-Kinase (PI3K) inhibitors Market – Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market by application (chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and other indications) and geography (Asia, Europe, North America, and ROW).
MEK Inhibitors Market– Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.